CQ Medical

Scientific Partner

Western University

Western University

CanaQuest has been the industry partner for research and product development with Dr. Steven Laviolette, a professor and neuroscientist, at Western University, London, Ontario Canada for five years. Dr. Laviolette is a scientific veteran with over 20 years of research experience in the field of mental health and cannabinoids and he oversees a dedicated team of 13 scientists. The team is focused on novel cannabinoid and botanical pharmacotherapies, addressing neurological conditions.

About Dr. Steven Laviolette:

Professor and Neuroscientist at the Schulich School of Medicine & Dentistry at Western University in London, Ontario, Dr. Laviolette is a leader in the study of cannabinoids in mental health and was recently awarded “Faculty Scholar” status. Dr. Laviolette’s research team has previously made numerous fundamental discoveries related to how cannabinoids impact and may serve as treatments for mental health disorders including schizophrenia, depression, post-traumatic stress disorder and anxiety. Dr. Laviolette’s primary research focus is on characterizing how specific phytochemical derivatives of cannabis may interact with specific brain pathways and molecular mechanisms whereby they may improve symptoms associated with various mental health disorders. Research from Dr. Laviolette’s team has been published in the world’s top tier of neuroscience and psychiatry journals. The following is a link to Dr. Laviolette’s profile on Western University’s website.  https://www.schulich.uwo.ca/anatomy/people/faculty/faculty_members/laviolette_steve.html

Dr. Laviolette and his team made the amazing discovery, a pure plant-based pharmaceutical-grade cannabidiol (CBD) isolate plus natural omega-3 active IP formula. Pre-clinical trial results have demonstrated that it effectively crosses the blood-brain barrier “BBB” to target neurological conditions such as anxiety, depression, PTSD, and addiction. www.laviolettelab.com